0000790502-15-000008.txt : 20150106 0000790502-15-000008.hdr.sgml : 20150106 20150106133504 ACCESSION NUMBER: 0000790502-15-000008 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150106 DATE AS OF CHANGE: 20150106 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Anacor Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001411158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 251854385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-85788 FILM NUMBER: 15509166 BUSINESS ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: 650-543-7500 MAIL ADDRESS: STREET 1: 1020 E. MEADOW CIRCLE CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Anacor Pharmaceuticals Inc DATE OF NAME CHANGE: 20070830 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: EAGLE ASSET MANAGEMENT INC CENTRAL INDEX KEY: 0000790502 IRS NUMBER: 592385219 STATE OF INCORPORATION: FL FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 880 CARILLON PARKWAY CITY: ST PETERSBURG STATE: FL ZIP: 33716 BUSINESS PHONE: 7275732453 MAIL ADDRESS: STREET 1: 880 CARILLON PARKWAY CITY: ST PETERSBURG STATE: FL ZIP: 33716 SC 13G 1 ANAC.txt ANACOR PHARMACEUTICALS, INC. January 6, 2015 Securities and Exchange Commission 100 F Street NE Washington, DC 20549 RE: Schedule 13G Anacor Pharmaceuticals, Inc. As of December 31, 2014 Gentlemen: In accordance with Section 13(d)(5) of the Securities Exchange Act of 1934, attached please find a copy of Schedule 13G for the above named company showing beneficial ownership of 5% or more as of December 31, 2014 filed on behalf of Eagle Asset Management, Inc. Very truly yours, Damian Sousa Vice President Chief Compliance Officer Enclosures cc: Office of the Corporate Secretary Anacor Pharmaceuticals, Inc. 1020 E. Meadow Circle Palo Alto, California 94303 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Anacor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032420101 (CUSIP Number) Check the following box if a fee is being paid with this statement _____. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 1 of 5 Pages CUSIP NO. 032420101 13G 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Eagle Asset Management, Inc. 59-2385219 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) ______ (B) ______ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION State of Florida NUMBER OF 5 SOLE VOTING POWER SHARES 2,328,177 BENEFICIALLY 6 SHARED VOTING POWER OWNED - - - AS OF DECEMBER 31, 2014 7 SOLE DISPOSITIVE POWER BY EACH 2,328,177 REPORTING 8 SHARED DISPOSITIVE POWER PERSON WITH - - - 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,328,177 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [_____] 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.43% 12 TYPE OF REPORTING PERSON* IA _____________________________________________________________ *SEE INSTRUCTION BEFORE FILLING OUT! _____________________________________________________________ Page 2 of 5 Pages Item 1(a) Name of Issuer: Anacor Pharmaceuticals, Inc. Item 1(b) Address of Issuer's Principal Executing Offices: 1020 E. Meadow Circle Palo Alto, California 94303 Item 2(a) Name of Person Filing: Eagle Asset Management, Inc. Item 2(b) Address of Principal Business Office: 880 Carillon Parkway St. Petersburg, Florida 33716 Item 2(c) Citizenship: Florida Item 2(d) Title of Class of Securities: Common Stock Item 2(e) CUSIP Number: 032420101 Item 3 Type of Reporting Person: (e) Investment Adviser registered under Section 203 of the Investment Advisors Act of 1940 Page 3 of 5 Pages Item 4 Ownership as of December 31, 2014 (a) Amount Beneficially Owned: 2,328,177 shares of common stock beneficially owned including: No. of Shares Eagle Asset Management, Inc. 2,328,177 (b) Percent of Class: 5.43% (c) Deemed Voting Power and Disposition Power: (i) (ii) (iii) (iv) Deemed Deemed Deemed Deemed to have to have to have to have Sole Power Shared Power Sole Power Shared Power to Dispose to Dispose to Vote or to Vote or or to or to to Direct to Direct Direct the Direct the to Vote to Vote Disposition Disposition Eagle Asset 2,328,177 ---- 2,328,177 ---- Management, Inc. Item 5 Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. (___) Item 6 Ownership of More than Five Percent on Behalf of Another Person: N/A Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company: N/A Page 4 of 5 Pages Item 8 Identification and Classification of Members of the Group: N/A Item 9 Notice of Dissolution of Group: N/A Item 10 Certification: By signing below I certify that to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 6, 2015 EAGLE ASSET MANAGEMENT, INC. /s/ Damian Sousa _________________________________ Damian Sousa Vice President Chief Compliance Officer Page 5 of 5 Pages